We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?
Read MoreHide Full Article
Key Takeaways
Cytokinetics' Myqorzo surpassed 700 U.S. prescribers, with over 40% new-to-brand prescription share by Q2.
Myqorzo launched in Germany, gained U.K. authorization and could enter additional markets through early 2027.
Cytokinetics plans an nHCM filing in Q4 2026, while the FDA set a Nov. 14 action date for its oHCM sNDA.
Cytokinetics, Incorporated (CYTK - Free Report) is making encouraging commercial progress with its lead drug, Myqorzo (aficamten), following its December 2025 approval for treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Adoption continued to expand, supported by growing physician awareness, prescribing activity, patient demand and market access.
More than 700 unique U.S. healthcare providers prescribed Myqorzo as of June 30. More than 80% of dispensed prescriptions were paid, while management’s internal analysis indicated that the drug exited the second quarter with more than 40% new-to-brand prescription share in the cardiac myosin inhibitor category.
Cytokinetics expanded Myqorzo’s international commercial reach with its June launch in Germany, marking the drug’s entry into its first European market. Myqorzo also received marketing authorization in the United Kingdom, where NICE recommended it for use in England and Wales. The company expects to launch the drug in additional markets later this year or in the first half of 2027.
Clinical developments could further strengthen Myqorzo’s growth prospects. Additional results from the phase III ACACIA-HCM study demonstrated improvements in cardiac structure and diastolic function in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM). The study had previously met both primary endpoints, showing statistically significant improvements in KCCQ Clinical Summary Score and maximal exercise performance (pVO2) versus placebo.
These findings suggest that aficamten’s potential benefits in nHCM may extend beyond improvements in symptoms and exercise capacity. With no approved therapies currently available for this indication, Cytokinetics plans to submit a supplemental new drug application (sNDA) in the fourth quarter of 2026. The approval could expand Myqorzo’s addressable market.
Separately, the FDA accepted the company’s sNDA based on the phase III MAPLE-HCM study, which evaluated aficamten as monotherapy against metoprolol in patients with oHCM. The FDA assigned a target action date of Nov. 14, 2026.
Continued commercial adoption, potential expansion into nHCM and launches in additional markets could support further Myqorzo sales growth and broaden its market opportunity.
Competition for CYTK’s Myqorzo
Myqorzo operates within an evolving treatment landscape for oHCM. Its primary branded competitor is Camzyos, a cardiac myosin inhibitor marketed by Bristol Myers Squibb (BMY - Free Report) . In addition to this direct competition, Myqorzo faces established generic therapies, namely beta blockers and calcium channel blockers, which continue to serve as the first-line standard of care.
BMY obtained FDA approval for Camzyos in 2022 for the treatment of adults with symptomatic New York Heart Association class II-III obstructive HCM to improve functional capacity and symptoms.
The drug continues to gain traction in its target market, supported by growing demand and broader adoption among eligible patients, potentially boosting BMY’s top line.
The FDA recently approved the drug for treating symptomatic oHCM to improve functional capacity and symptoms in adults and pediatric patients weighing 30 kg (66 lbs) or more.
A potential competitor for Cytokinetics is Edgewise Therapeutics, Inc. (EWTX - Free Report) , which is advancing a cardiovascular pipeline targeting HCM, heart failure, and other cardiovascular and cardiometabolic conditions.
EWTX’s lead candidate, EDG-7500, is a novel, oral, selective cardiac sarcomere modulator currently being studied in a multipart phase II study in patients with oHCM and nHCM, with a phase III program targeted to be launched in the fourth quarter of 2026.
The company’s pipeline also includes EDG-15400 for heart failure. It recently announced the dosing of the first patient in EQUINOX-HFpEF, a phase II study evaluating EDG-15400 in adults with symptomatic heart failure with preserved ejection fraction who have a left ventricular ejection fraction of at least 50%.
View the Zacks #1 Rank List
Image: Bigstock
Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?
Key Takeaways
Cytokinetics, Incorporated (CYTK - Free Report) is making encouraging commercial progress with its lead drug, Myqorzo (aficamten), following its December 2025 approval for treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Adoption continued to expand, supported by growing physician awareness, prescribing activity, patient demand and market access.
More than 700 unique U.S. healthcare providers prescribed Myqorzo as of June 30. More than 80% of dispensed prescriptions were paid, while management’s internal analysis indicated that the drug exited the second quarter with more than 40% new-to-brand prescription share in the cardiac myosin inhibitor category.
Cytokinetics expanded Myqorzo’s international commercial reach with its June launch in Germany, marking the drug’s entry into its first European market. Myqorzo also received marketing authorization in the United Kingdom, where NICE recommended it for use in England and Wales. The company expects to launch the drug in additional markets later this year or in the first half of 2027.
Clinical developments could further strengthen Myqorzo’s growth prospects. Additional results from the phase III ACACIA-HCM study demonstrated improvements in cardiac structure and diastolic function in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM). The study had previously met both primary endpoints, showing statistically significant improvements in KCCQ Clinical Summary Score and maximal exercise performance (pVO2) versus placebo.
These findings suggest that aficamten’s potential benefits in nHCM may extend beyond improvements in symptoms and exercise capacity. With no approved therapies currently available for this indication, Cytokinetics plans to submit a supplemental new drug application (sNDA) in the fourth quarter of 2026. The approval could expand Myqorzo’s addressable market.
Separately, the FDA accepted the company’s sNDA based on the phase III MAPLE-HCM study, which evaluated aficamten as monotherapy against metoprolol in patients with oHCM. The FDA assigned a target action date of Nov. 14, 2026.
Continued commercial adoption, potential expansion into nHCM and launches in additional markets could support further Myqorzo sales growth and broaden its market opportunity.
Competition for CYTK’s Myqorzo
Myqorzo operates within an evolving treatment landscape for oHCM. Its primary branded competitor is Camzyos, a cardiac myosin inhibitor marketed by Bristol Myers Squibb (BMY - Free Report) . In addition to this direct competition, Myqorzo faces established generic therapies, namely beta blockers and calcium channel blockers, which continue to serve as the first-line standard of care.
BMY obtained FDA approval for Camzyos in 2022 for the treatment of adults with symptomatic New York Heart Association class II-III obstructive HCM to improve functional capacity and symptoms.
The drug continues to gain traction in its target market, supported by growing demand and broader adoption among eligible patients, potentially boosting BMY’s top line.
The FDA recently approved the drug for treating symptomatic oHCM to improve functional capacity and symptoms in adults and pediatric patients weighing 30 kg (66 lbs) or more.
A potential competitor for Cytokinetics is Edgewise Therapeutics, Inc. (EWTX - Free Report) , which is advancing a cardiovascular pipeline targeting HCM, heart failure, and other cardiovascular and cardiometabolic conditions.
EWTX’s lead candidate, EDG-7500, is a novel, oral, selective cardiac sarcomere modulator currently being studied in a multipart phase II study in patients with oHCM and nHCM, with a phase III program targeted to be launched in the fourth quarter of 2026.
The company’s pipeline also includes EDG-15400 for heart failure. It recently announced the dosing of the first patient in EQUINOX-HFpEF, a phase II study evaluating EDG-15400 in adults with symptomatic heart failure with preserved ejection fraction who have a left ventricular ejection fraction of at least 50%.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.